Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 7/20 | 0.49 |
| ▸ | RET | P07949 | 10/20 | 0.49 |
| ▸ | KIF5B | P33176 | 4/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6055489 | 0.89 | KDR (0.55) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL3673970 | 0.85 | KDR (0.67) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL3674417 | 0.84 | KDR (0.60) | KDREGFRRETKIF5BERBB2 | |
| SCHEMBL6881088 | 0.84 | KDR (0.66) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL3671772 | 0.84 | KDR (0.66) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL6881082 | 0.84 | KDR (0.66) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL3676968 | 0.83 | SRC (0.76) | KDRSRCEGFR | |
| Hydrochloric Acid SCHEMBL7582556 | 0.82 | EGFR (0.66) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL3673758 | 0.81 | SRC (0.62) | KDRSRCEGFRRETKIF5B | |
| SCHEMBL6871732 | 0.81 | KDR (0.68) | KDRSRCEGFRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | US | claimed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | US | disclosed |
| EP-1332141-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063733-A1 | Such as 4-(7-indolylamino)-6-methoxy-7-(3-morpholinopropoxy)-quinazoline; for treating solid tumors | MIF, CCNI, MMP7 | KDR 1855/4885SRC 1355/4885EGFR 862/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | KDR 825/4885SRC 1/4885EGFR 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.